This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2008 Oct;7(10):864-6.

doi: 10.1016/S1474-4422(08)70201-1. Epub 2008 Sep 11.

REGARD: what can we learn from randomised, open-label, head-to-head studies?

Per Soelberg Sørensen

PMID: 18789767
DOI: 10.1016/S1474-4422(08)70201-1

Comment

REGARD: what can we learn from randomised, open-label, head-to-head studies?

Per Soelberg Sørensen. Lancet Neurol. 2008 Oct.

. 2008 Oct;7(10):864-6.

doi: 10.1016/S1474-4422(08)70201-1. Epub 2008 Sep 11.

Author

Per Soelberg Sørensen

PMID: 18789767
DOI: 10.1016/S1474-4422(08)70201-1

No abstract available

PubMed Disclaimer

Comment on

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitdehaag B; REGARD study group. Mikol DD, et al. Lancet Neurol. 2008 Oct;7(10):903-14. doi: 10.1016/S1474-4422(08)70200-X. Epub 2008 Sep 11. Lancet Neurol. 2008. PMID: 18789766 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science